物质信息

ID:349377

名称和标识
别名
(R)-Simendan2-[2-[4-[(4R)-1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazinylidene]-propanedinitrileOR 1259R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrileLevosimendan(-)-OR-1259
IUPAC标准名
1-cyano-N-{4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}methanecarbohydrazonoyl cyanide
IUPAC传统名
levosimendan
数据登录号
化合物性质
产品相关信息
Empirical Formula (Hill Notation)
C14H12N6O
纯度
≥98% (HPLC)
理化性质
溶解度
DMSO: ≥20 mg/mL
外观
yellow powder
比旋光度
[α]/D -500 to -650°, c = 0.5 in THF
安全信息
GHS危险声明
H302-H312-H332
GHS危险品标识
GHS07
急性毒性(口服,皮肤接触,吸入),类别4
皮肤刺激,类别2
眼刺激,类别2
皮肤过敏,类别1
特定目标器官毒性 -一次接触,类别3
GHS警示词
Warning
危险公开号
20/21/22
GHS警示性声明
P280
MSDS下载
德国WGK号
3
欧盟危险性物质标志
有害性 有害性 (Xn)
安全公开号
36/37
保存温度
room temp
RTECS编号
TY1570210
描述信息
Biochem/physiol Actions
Levosimendan is a calcium sensitiser. The compound increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan binds to cardiac troponin C in a calcium-dependent manner and stabilizes troponin C. This is followed by actin-myosin cross-bridges, without increasing myocardial consumption of ATP. Additionally the compound acts as vasodilator by opening an ATP-sensitive potassium channels. Levosimendan is a drug used for treatment of congestive heart failure. Also it can be used to treat calcium channel blocker overdose.
分子图谱
暂无数据
点击上传数据
参考文献
暂无数据
点击上传数据